News Releases

BALLINA, Co. Tipperary (Ireland) and BREA, Calif. (USA) – (March 15, 2018) — Long-term agreement expands Beckman Coulter customers’ access to high-quality QC products, supporting efficient...

Fully contained automation solution boosts laboratory productivity, workflow flexibility and testing quality BREA, Calif. — (Feb. 20 2018) — Beckman Coulter Diagnostics and NTE-SENER, the...

Beckman Coulter Diagnostics today announced the addition of 6-Acetylmorphine (6-AM) and Buprenorphine (BUP) assays to its broad menu of drugs-of-abuse tests that meet the demands of onsite testing...

Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic (IVD) use in the U.S. This simple test aids healthcare providers in the...

Beckman Coulter is committed to ensuring customers receive the highest quality assays, on-time, to help healthcare and laboratory professionals provide better patient care. To further these goals,...

A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when phi testing was included in their overall, routine, clinical assessment.

New assay enables hospitals to provide efficiency improvements in cardiac patient management BREA, Calif. —(Nov. 7, 2017) — Beckman Coulter Diagnostics announced today that it has received CE...

Beckman Coulter Diagnostics is pleased to announce worldwide availability of the Access 2 immunoassay system with enhanced features. Built upon a 20-year legacy of reliable and efficient...

Beckman Coulter Diagnostics introduces its DxONE information management solutions, an integrated system of technologies and capabilities, designed to ease data access and usability. DxONE is...

Beckman Coulter Diagnostics, a global leader in the clinical diagnostics industry will present its global initiative, "Partnering Today for a Stronger Tomorrow," at the 69th American Association...